|
|
| |
 |
Gamma irradiation can be used to inactivate Bacillus anthracis spores without compromising the sensitivity of diagnostic assays
From Jul Appl Environ Microbiol
|
|
|
Birth defects among infants born to women who received anthrax vaccine in pregnancy
From Am J Epidemiol, published online Jul 2
|
|
|
Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background
From Jul Clin Vaccine Immunol
|
|
|
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax
From Antimicrob Agents Chemother, published online Jul 7
|
|
|
Occurrence and genetic diversity of Bacillus anthracis strains isolated in an active wool-cleaning factory
From Jul Appl Environ Microbiol
|
|
|
Analysis of suspicious powders following the post 9/11 anthrax scare
|
|
|
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis
From Jun Antimicrob Agents Chemother
|
|
|
Cutaneous anthrax associated with drum making using goat hides from West Africa--Connecticut, 2007
|
|
|
Inhalation anthrax: dose response and risk analysis
From Jun Biosecur Bioterror
|
|
|
Modeling the incubation period of inhalational anthrax
From Med Decis Making, published online Jun 12
|
|
|
Human serum contains a protease that protects against cytotoxic activity of Bacillus anthracis lethal toxin in vitro
From Jun Clin Vaccine Immunol
|
|
|
Anthrax: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis
CIDRAP-authored overview updated May 30 with new research
|
|
|
Inactivation of Bacillus anthracis spores by a combination of biocides and heating under high-temperature short-time pasteurization conditions
From Jun Appl Environ Microbiol
|
|
|
In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin
From Jun Antimicrob Agents Chemother
|
|
|
A review of management practices for the control of anthrax in animals: the 2005 anthrax epizootic in North Dakota - case study
From Zoonoses Public Health, published online May 16
|
|
|
The immunogenicity of Bacillus anthracis protective antigen domains and the efficacy of elicited antibody responses depend on host genetic background
From Clin Vaccine Immunol, published online May 14
|
|
|
Conference report on public health and clinical guidelines for anthrax
From Apr Emerg Infect Dis
|
|
|
Detoxified lethal toxin as a potential mucosal vaccine against anthrax
From Apr Clin Vaccine Immunol
|
|
|
Decontamination of fluid milk containing Bacillus spores using commercial household products
|
|
|
Treatment of experimental anthrax with recombinant capsule depolymerase
From Mar Antimicrob Agents Chemother
|
|
|
Detection of Bacillus anthracis spore germination in vivo by bioluminescence imaging
|
|
|
Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among US military personnel
|
|
|
Inactivation kinetics of avirulent Bacillus anthracis spores in milk with a combination of heat and hydrogen peroxide
|
|
|
Rat survival to anthrax lethal toxin is controlled by a single gene
From Feb Pharmacogenomics J
|
|
|
Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses
|
|
|
Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor
From Jan Clin Vaccine Immunol
|
|
